Etid klinik pou Lupus nan Arizona
7 etid pou Lupus ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Phoenix
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Phoenix
- Research Site, Tucson
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Mayo Clinic, Phoenix
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50058, Avondale
- Sl0044 50550, Chandler
- Sl0044 50713, Gilbert
- ak 3 plis
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06617325A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- HonorHealth Research and Innovation Institute, Scottsdale
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 21, 2026 · NCT06570798A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- AARA Clinical Research, Avondale
- AARA Clinical Research, Tucson
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 5, 2026 · NCT06613360Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Arizona, Tucson
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.